2011-08-15T10:41:00-05:00 2010-09-30 Clark Nuber PS 10900 NE 4th Street Suite 1700 Bellevue WA 98004 990 2009-10-01 910667886 PACIFIC NORTHWEST RESEARCH INSTITUTE PACI 2067261200 720 BROADWAY SEATTLE WA 98122 RICHARD J OMATA 2067261200 2011-08-11 1 Jane M Searing 4254544919 2009 2016-02-24 21:20:13Z PACIFIC NW DIABETES RESEARCH INST RICHARD J OMATA 720 BROADWAY SEATTLE WA 98122 6384241 0 X WWW.PNRI.ORG X 1956 WA PNDRI'S MISSION IS TO CONDUCT RESEARCH THAT LEADS TO THE PREVENTION AND CURE OF DIABETES. 13 13 129 76 0 0 6078695 5997632 25400 50928 81805 72587 42064 102539 6227964 6223686 0 0 4444206 3829792 0 184131 2104389 2154531 6548595 5984323 -320631 239363 14266215 14884234 2043605 2104021 12222610 12780213 PNDRI CONDUCTS BASIC RESEARCH AND CLINICAL STUDIES RELATED TO THE PREVENTION AND CURE OF DIABETES AND ITS COMPLICATIONS. PNDRI'S RESEARCH LEADS TO EARLY IDENTIFICATION OF INDIVIDUALS (NEWBORNS) PREDISPOSED TO T 1 DIABETES AND THERAPIES TO CURE, PREVENT OR DELAY ONSET OF THE DISEASE. IN THE FISCAL YEAR, PNDRI PROVIDED OVER 30,000 FREE T1 HLA DIABETES SCREENINGS FOR PARENTS OF NEWBORNS IN WASHINGTON STATE. PNDRI CONTINUES TO BE A LEADER IN T2 DIABETES RESEARCH AND IS MAKING SIGNIFICANT ADVANCES RELATED TO UNDERSTANDING GLUCOSE TOXICITY AND OXIDATIVE STRESS IN THE BETA CELLS IN ADULTS WITH T2 DIABETES. PNDRI RESEARCHERS HAVE ALSO COMPLETED MORE THAN 500 PANCREAS AND ISLET TRANSPLANTATIONS IN HUMANS. WE ARE CURRENTLY RUNNING CLINICAL TRIALS FOR NON-PRESCRIPTION THERAPY FOR T2 DIABETES. 0 0 3155258 PNDRI CONDUCTS BASIC RESEARCH AND CLINICAL STUDIES RELATED TO THE PREVENTION AND CURE OF DIABETES AND ITS COMPLICATIONS. RECENTLY THE INSTITUTE HAS DEMONSTRATED THE TECHNICAL FEASIBILITY OF NEWBORN GENETIC SCREENING FOR TYPE 1 DIABETES WASHINGTON STATE-WIDE. THE NEWBORN DIABETES SCREENING PROGRAM'S PRIMARY OBJECTIVE IS IDENTIFYING WHICH NEWBORNS ARE AT HIGH RISK OF TYPE 1 DIABETES, DUE TO THEIR GENETIC MAKE-UP. THE PROGRAM HAS HELPED FAMILIES WHO KNOW IF THEIR CHILD IS AT HIGH RISK BY PREVENTING DEATH, PROLONGED HOSPITAL ICU STAYS, AND EXTREME ILLNESS AT DISEASE ONSET; THUS THE PROGRAM HAS SIGNIFICANTLY REDUCED ASSOCIATED MEDICAL CARE COSTS. 1964127 50928 WITH REGARD TO THE MOST PREVALENT FORM OF DIABETES, TYPE 2 DIABETES, RESEARCHERS AT THE INSTITUTE HAVE DISCOVERED A LINK BETWEEN THAT DISEASE AND ANTI-OXIDANTS. AS A RESULT, A HUMAN CLINICAL TRIAL OF A POTENT ANTI-OXIDANT, N-ACETYL CYSTEINE IS UNDERWAY TREATING MILITARY VETERANS AND NATIVE AMERICAN PATIENT GROUPS. BOTH OF THESE POPULATION GROUPS HAVE EXPERIENCED AN INCREASED RISK FOR DIABETES. WE ALSO WORK ON CONTINUED RESEARCH TO IDENTIFY OTHER POTENTIAL TREATMENTS. 5119385 1 1 0 0 0 0 0 0 1 1 1 0 0 0 0 0 0 0 1 0 0 0 0 1 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 1 36 0 1 129 1 0 0 0 0 0 1 1 0 0 0 13 13 0 0 0 0 0 0 0 1 1 0 0 1 1 1 1 1 1 0 1 0 WA X BRYON M EPP 2067261200 720 BROADWAY SEATTLE WA 98122 RICHARD J OMATA 10.00 X X 0 0 0 ARDYTHE JOHNSON 8.00 X X 0 0 0 SARAH ARMSTRONG 4.00 X X 0 0 0 GILLIAT G SCHROEDER JR 8.00 X X 0 0 0 KARL L ASCHENBACH 4.00 X 0 0 0 LOIS JEAN BROADWAY 4.00 X 0 0 0 DAN CALDWELL 4.00 X 0 0 0 BARRY ERICKSON 4.00 X 0 0 0 JUANITA M GARRISON 4.00 X 0 0 0 CAROL L HEIMKES 4.00 X 0 0 0 LYNN KERN 4.00 X 0 0 0 JAMES M NORMAN 4.00 X 0 0 0 DOUG SHAW 8.00 X 0 0 0 JERRY P PALMER 4.00 X 0 0 0 JAMES GORE 40.00 X 227963 0 20180 BRYON EPP CPA 40.00 X 90287 0 15872 JACK FARIS 40.00 X 0 0 0 WILLIAM HAGOPIAN MDPHD 40.00 X 166579 0 16574 JOSEPH BRYAN PHD 40.00 X 162545 0 13549 R PAUL ROBERTSON MD 40.00 X 157828 0 15007 ANDREY BABENKO PHD 40.00 X 126340 0 4271 931542 0 85453 5 0 1 0 0 136950 4609036 1251646 90835 5997632 ANALYTICAL FEES 900099 36560 36560 VIVARIUM FEES 900099 14368 14368 50928 63087 63087 198868 50244 148624 148624 148624 9500 9500 9500 9500 47817 136950 110311 -62494 -62494 HONORARIUMS 900099 15501 15501 MISCELLANEOUS 900099 908 908 16409 6223686 50928 0 175126 558782 486501 53244 19037 2610358 2261001 259347 90010 48592 44074 3023 1495 341175 309456 21226 10493 270885 232961 29797 8127 11782 3981 7123 678 52015 17574 31448 2993 294 294 219434 102456 106250 10728 725375 679020 25036 21319 7273 6926 328 19 257789 212446 42803 2540 60725 59207 920 598 28258 20646 3258 4354 50883 49745 509 629 342110 279102 59478 3530 53374 44114 8741 519 PATIENT COSTS 197840 197840 EQUIPMENT COSTS 98029 94713 2587 729 DUES, FEES & LICENSES 29938 17601 6004 6333 TAXES 12205 21 12184 CHARITABLE ANNUITY PMT 7160 7160 47 47 5984323 5119385 680807 184131 440666 894344 358546 942491 1374114 901310 13799 7585 158677 185168 11734414 6092922 5910421 5641492 2620757 2639969 3389235 3671875 14266215 14884234 562205 958975 1175000 965000 306400 180046 2043605 2104021 X 8501772 9102802 485234 334041 3235604 3343370 12222610 12780213 14266215 14884234 X 0 1 1 X 1 1 X 5924852 4704320 6544943 6078695 5997632 29250442 16672 21742 74183 25400 50928 188925 5941524 4726062 6619126 6104095 6048560 29439367 35500 12420 33686 81606 0 35500 12420 33686 81606 29357761 267613 236200 236837 221786 277456 1239892 267613 236200 236837 221786 277456 1239892 19497 60770 80267 10 908 918 6228634 5023032 6855963 6325891 6326924 30760444 0.95440 0.95810 0.04030 0.03740 X Schedule A, Part IV, Supplemental Information: PART III, COLUMN D, LINE 12: MISCELLANEOUS INCOME $10 PART III, COLUMN E, LINE 12: MISCELLANEOUS INCOME $908 RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 2627730 2552730 75000 2591108 36622 2627730 0.00000 1.00000 0.00000 0 0 823359 823359 9177494 4625430 4552064 1733561 1467492 266069 5641492 SPLIT INTEREST AGREEMENTS 238072 PERPETUAL TRUST 3268370 BEQUESTS RECEIVABLE 165433 3671875 ANNUITY OBLIGATION 12185 CAPITAL LEASE PAYABLE 167861 180046 6223686 5984323 239363 119637 198603 318240 557603 6702481 119637 198603 318240 6384241 -160555 -160555 6223686 6144878 160555 160555 5984323 0 5984323 Part V, Line 4: Description of Intended Use of Endowment Funds: THE ORGANIZATION'S ENDOWMENT FUNDS ARE DESIGNATED FOR USE AS OPERATING RESERVES AND SCIENTIST RECRUITMENT. Part XI, Line 8 - Other Adjustments: CHANGE IN VALUE OF SPLIT INTEREST AGREEMENT: 90837. GAIN ON PERPETUAL TRUST: 107766. Part XII, Line 2d - Other Adjustments: CHANGE IN VALUE OF SPLIT INTEREST AGREEMENT: 90837. GAIN ON PERPETUAL TRUST: 107766. Part XII, Line 4b - Other Adjustments: SPECIAL EVENT EXPENSE NETTED AGAINST SPECIAL EVENT REVENUE: -110311. RENTAL EXPENSES: -50244. Part XIII, Line 2d - Other Adjustments: SPECIAL EVENT EXPENSE NETTED AGAINST SPECIAL EVENT REVENUE: 110311. RENTAL EXPENSES: 50244. PART V - ENDOWMENT FUNDS: AT SEPTEMBER 30, 2009 PNDRI REPORTED $2,552,730 OF BOARD DESIGNATED QUASI-ENDOWMENT FUNDS. IN DECEMBER 2009, THE BOARD OF TRUSTEES TOOK ACTION TO CLARIFY THAT THE INVESTMENT FUNDS ON HAND ARE BOARD DESIGNATED RESERVES AND NOT INTENDED TO BE AN ENDOWMENT. THEREFORE, THE INVESTMENT FUNDS HELD AS QUASI-ENDOWMENT FUNDS WERE RECLASSIFIED TO BOARD-DESIGNATED RESERVES AT SEPTEMBER 30, 2010. WINE EVENT 184767 136950 47817 26071 26769 5500 51971 184767 136950 47817 26071 26769 5500 51971 110311 -62494 X 0 0 0 0 0 0 0 0 0 JAMES GORE 227963 0 0 0 0 0 6702 0 13478 0 248143 0 0 0 WILLIAM HAGOPIAN MDPHD 166579 0 0 0 0 0 4596 0 11978 0 183153 0 0 0 JOSEPH BRYAN PHD 162545 0 0 0 0 0 4952 0 8597 0 176094 0 0 0 R PAUL ROBERTSON MD 157828 0 0 0 0 0 4974 0 10033 0 172835 0 0 0 X 1 2570 FMV X 3 88265 COST OR SELLING PRICE 0 0 1 0 Method for Determining Number of Contributors: Part I, Column (b): SCHEDULE M, PART I, COLUMN (B): THE AMOUNT IN PART I, COLUMN B IS THE NUMBER OF CONTRIBUTIONS RECEIVED. Form 990, Part VI, Section B, line 11 THE FORM 990 IS REVIEWED BY THE AUDIT COMMITTEE WITH HIGHLIGHTS DISCUSSED AT THE BOARD MEETING. COPIES OF THE 990 WILL BE SENT ELECTRONICALLY TO THE ENTIRE BOARD BEFORE FILING WITH THE IRS. Form 990, Part VI, Section B, line 12c ANNUALLY, PER WRITTEN CONFLICT OF INTEREST POLICY THE AUDIT COMMITTEE SUBMITS A BOARD QUESTIONNAIRE TO ALL TRUSTEES AND KEY STAFF. ALL RESPONSES ARE GATHERED AND THEN DISCUSSED AT THE AUDIT COMMITTEE MEETING. THE AUDIT COMMITTEE THEN PRESENTS THE RESULTS TO THE FULL BOARD AND ACTION IS TAKEN AS NEEDED. IF A POTENTIAL CONFLICT OF INTEREST AROSE DURING THE YEAR, THE BOARD MEMBER WOULD CONTACT OUR AUDIT COMMITTEE AND DISCLOSE THE MATTER AND BOARD REVIEW AND ACTION WOULD BE TAKEN AT THE NEXT MEETING TO ALERT ALL MEMBERS. Form 990, Part VI, Section B, line 15b THE VICE PRESIDENT, CFO, AND KEY EMPLOYEES HAVE THEIR INITIAL SALARY AND ANY NON-COST OF LIVING ADJUSTMENT INCREASES DOCUMENTED BY A SALARY SURVEY PROCESS CONDUCTED BY OUR INDEPENDENT HUMAN RESOURCES CONSULTING FIRM. THE TOP MANAGEMENT OFFICIAL POSITION IS CURRENTLY AN UNCOMPENSATED POSITION. Form 990, Part VI, Section C, line 19 GOVERNING DOCUMENTS, CONFLICT OF INTEREST POLICY AND FINANCIAL STATEMENTS ARE AVAILABLE UPON REQUEST. FORM 990, PART 1, LINE 6: VOLUNTEERS VOLUNTEERS PROVIDE SUPPORT FOR DIABETES RESEARCH CONDUCTED IN LABS, ADMINISTRATION AND GOVERNANCE SERVICES, AND SUPPORT FOR FUNDRAISING ACTIVITIES. 14 VOLUNTEERS SERVE AS BOARD MEMBERS.